A recent study found that a proprietary amla ingredient from Sabinsa, called Saberry, supported blood sugar parameters in diabetic subjects.
Photo © AdobeStock.com/ 6okean
A recent study1 found that a proprietary amla ingredient from Sabinsa (East Windsor, NJ), called Saberry, supported blood sugar parameters in diabetic subjects. In the 90-day, multicentric randomized open label trial, 124 newly diagnosed diabetic subjects between the ages of 30 and 65 with diabetic dyslipidemia were randomized to receive either 1 g per day of the amla extract, 2 g per day of the amla extract, or 500 mg per day of metformin for 90 days.
Results showed that all the treatment groups saw significant reductions in fasting blood sugar and postprandial blood sugar (FBS and PPBS), hemoglobin A1c (HbA1c) and lipid levels. Subjects receiving 2 g per day of the amla extract had significantly higher reductions of FBS, PPBS and HbA1c, compared to metformin and 1 g per day of the amla extract. Reductions in LDL and total cholesterol were also significantly higher among those taking 2 g per day of the amla extract compared to 1 g per day of amla, and comparable to the metformin group.
Reference
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
FDA and FTC issue more warning letters to copycat delta-8 THC food products
July 16th 2024The U.S. Food and Drug Administration and Federal Trade Commission have jointly issued warning letters to five companies for selling copycat food products containing delta-8 THC in violation of the Federal Food Drug and Cosmetic Act.